Address
Elm Street Ventures
33 Whitney Avenue
New Haven, CT 06510
United States
Phone
Email
Website
Recent investment activity
KANDO id: 30173
Corporate information
Registration country
Funding rounds
Actual initial investment stage
Seed (1)
Investment activity status
Active investor
Selected investments
Displaying 1 - 13 of 13| Company | Profile | Country | Date | Funding | ||
|---|---|---|---|---|---|---|
| |
Desmos Inc | K-12 online math content and tools enabling mathematical visualization, fluency and curriculum. | N/A | |||
| |
Iconic Therapeutics Inc | Therapeutic for the wet form of Age-related Macular Degeneration. | N/A | |||
| |
Kolltan Pharmaceuticals Inc | Oncology therapeutics company, develops monoclonal antibody drugs targeting receptor tyrosine kinases. | N/A | |||
| |
Occam Sciences Inc | Therapeutic drug development company using green chemistry to design drugs that are more bioavailable. | N/A | |||
| |
P2 Science Inc | Unique bio-refining process company for the conversion of biomass. | N/A | |||
| |
Retail Optimization Inc | Provider of predictive space and assortment optimization analytics. | Series B | |||
| |
Samara Innovations LLC | Athletic apparel company for female athletes providing protection from injury and enhanced performance. | N/A | |||
| |
ShareGrove Inc | Browser-based software company that integrates communication, social networking, and web content. | Seed | |||
| |
Advanced Orthopedic Technologies Inc | Medical device company for cartilage. | N/A | |||
| |
Affomix Corp | Biotechnology company developing an automated approach for obtaining very large numbers of antibodies. | N/A | |||
| |
BioRelix Inc | Advanced fight against drug resistant microbes by attacking novel targets with novel drugs. | Series A Follow-on investment | |||
| |
BioRelix Inc | Advanced fight against drug resistant microbes by attacking novel targets with novel drugs. | Seed Initial investment | |||
| |
Metagenomix Inc | Seed |
Former team members
| Employee | Company | Position | |||
|---|---|---|---|---|---|
| Jon Edelson | Ascent Biomedical Ventures | [email protected] |